Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 4 of 13 for:    bacterial vaginosis | NIH

Treatment of Bacterial Vaginosis (BV) With Tinidazole

This study has been completed.
Information provided by:
University of Alabama at Birmingham Identifier:
First received: June 7, 2006
Last updated: May 24, 2011
Last verified: February 2011

We are trying to determine if treatment of bacterial vaginosis with tinidazole is better than treatment with metronidazole

Condition Intervention Phase
Bacterial Vaginosis
Drug: tinidazole, metronidazole
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Tinidazole for the Treatment of Bacterial Vaginosis

Resource links provided by NLM:

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • Cure of Bacterial Vaginosis [ Time Frame: one month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Recurrence of BV [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 593
Study Start Date: November 2004
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: control
metronidazole 500 BID for 7 days
Drug: tinidazole, metronidazole
Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
Other Name: Tindamax, Flagyl
Active Comparator: tinidazole 500
tinidazole 500 BID for 7 days
Drug: tinidazole, metronidazole
Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
Other Name: Tindamax, Flagyl
Active Comparator: tinidazole 1 gm
tinidazole 1 gm BID for 7 days
Drug: tinidazole, metronidazole
Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
Other Name: Tindamax, Flagyl

Detailed Description:

Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the U.S. and has been associated with complications including preterm delivery of infants, pelvic inflammatory disease (PID), urinary tract infections (UTI) and acquisition/transmission of sexually transmitted diseases (STDs) including human immunodeficiency virus (HIV). Control of BV has been advocated as a means of decreasing the prevalence of these complications. However, the etiology of BV remains unknown and the current treatment regimens are inadequate in terms of initial cure and recurrence rates. Although not currently licensed in the U.S., tinidazole is an antimicrobial related to metronidazole which has shown promise for the treatment of BV in European studies and is widely used worldwide for the treatment of trichomoniasis including infections which are resistant to metronidazole. We hypothesize that qualities of tinidazole such as its longer half-life and its seemingly superior side effect profile as compared to oral metronidazole will result in its being a more efficacious drug for the treatment of BV than the currently available options.

The specific aims of this project are:

  1. To compare the efficacy of two different doses of tinidazole with oral metronidazole for the initial treatment of symptomatic BV as well as short-term recurrence rates
  2. To compare the side effect profiles of tinidazole versus metronidazole in the treatment of BV
  3. To compare drug levels of tinidazole and metronidazole in the vaginal secretions and correlate with microbiologic cure of BV as well as rates of recurrence.

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women be at least 18 years of age
  • Have symptoms of vaginal odor and or/discharge
  • Meet the clinical (Amsel) criteria for BV
  • Willing to participate in research

Exclusion Criteria:

  • Presence of another vaginal infection or STD
  • Allergy to metronidazole
  • Pregnant or nursing
  • Use of oral or intravaginal antibiotics within the past 2 weeks
  • HIV or other chronic disease
  • Inability to keep return appointments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00334633

United States, Alabama
Jefferson County Department of Health STD Clinic
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: Jane Schwebke, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: Jane Schwebke , MD, University of Alabama at Birmingham Identifier: NCT00334633     History of Changes
Other Study ID Numbers: F040329003, R01AI058033
Study First Received: June 7, 2006
Results First Received: March 3, 2011
Last Updated: May 24, 2011
Health Authority: United States: Federal Government

Keywords provided by University of Alabama at Birmingham:
bacterial vaginosis

Additional relevant MeSH terms:
Vaginosis, Bacterial
Bacterial Infections
Genital Diseases, Female
Vaginal Diseases
Alkylating Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Antitrichomonal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on February 27, 2015